Literature DB >> 31004214

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.

Zoé L E van Kempen1, Johannis A van Rossum2, Djoeke Doesburg2, Iris Claessen3,4, Annick de Vries3,4, Anja Ten Brinke3,4, Bob W van Oosten2, Theo Rispens3,4, Joep Killestein2.   

Abstract

Entities:  

Year:  2019        PMID： 31004214     DOI： 10.1007/s00415-019-09327-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Authors:  Per Soelberg Sørensen; Poul Erik Hyldgaard Jensen; Aiden Haghikia; Malin Lundkvist; Christian Vedeler; Finn Sellebjerg; Nils Koch-Henriksen; Anna Fogdell-Hahn; Kjell-Morten Myhr; Jan Hillert; Ralf Gold
Journal:  Mult Scler       Date:  2011-04-20       Impact factor: 6.312

2.  Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.

Authors:  Rabab Debs; Elisabeth Maillart; Robert Fahed; Caroline Papeix; Charles Duyckaerts; Christine Stadelmann; Damien Galanaud; Catherine Lubetzki
Journal:  Neurology       Date:  2015-10-09       Impact factor: 9.910

3.  Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.

Authors:  Begoña Oliver; Oscar Fernández; Teresa Orpez; Marcos Papais Alvarenga; María Jesús Pinto-Medel; Miguel Guerrero; Antonio León; José Carlos López-Madrona; Rafael Maldonado-Sánchez; Juan Antonio García-León; Gloria Luque; Victoria Fernández; Laura Leyva
Journal:  Mult Scler       Date:  2010-12-21       Impact factor: 6.312

4.  Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Authors:  Anke Vennegoor; Theo Rispens; Eva Mm Strijbis; Alexandra Seewann; Bernard Mj Uitdehaag; Lisanne J Balk; Frederik Barkhof; Chris H Polman; Gertjan Wolbink; Joep Killestein
Journal:  Mult Scler       Date:  2012-09-19       Impact factor: 6.312

5.  Prediction of antibody persistency from antibody titres to natalizumab.

Authors:  Poul Erik H Jensen; Nils Koch-Henriksen; Finn Sellebjerg; Per S Sørensen
Journal:  Mult Scler       Date:  2012-03-27       Impact factor: 6.312

6.  Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Authors:  Theo Rispens; Astrid van Leeuwen; Anke Vennegoor; Joep Killestein; Rob C Aalberse; Gerrit J Wolbink; Lucien A Aarden
Journal:  Anal Biochem       Date:  2011-01-07       Impact factor: 3.365

7.  The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Authors:  P A Calabresi; G Giovannoni; C Confavreux; S L Galetta; E Havrdova; M Hutchinson; L Kappos; D H Miller; P W O'Connor; J T Phillips; C H Polman; E-W Radue; R A Rudick; W H Stuart; F D Lublin; A Wajgt; B Weinstock-Guttman; D R Wynn; F Lynn; M A Panzara
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

8.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

9.  α4-integrin receptor desaturation and disease activity return after natalizumab cessation.

Authors:  Tobias Derfuss; John M Kovarik; Ludwig Kappos; Marina Savelieva; Richa Chhabra; Avinash Thakur; Ying Zhang; Heinz Wiendl; Davorka Tomic
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.